Skip to content

    Emergent BioSolutions (EBS) stock price & financials

    View EBS earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance31.2% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $293.80M
    $194.70M
    $222.20M
    $140.90M
    $231.10M
    -21.3%
    $148.70M
    -23.6%
    $156.10M
    -29.7%
    $234.30M
    +66.3%
    Strengthening
    Operating Profit
    $64.50M
    -$9.50M
    $49.90M
    $1.60M
    $76.50M
    +18.6%
    -$27.90M
    -193.7%
    $10.50M
    -79.0%
    -$125.10M
    -7918.8%
    Weakening
    Net Profit
    $114.80M
    -$31.30M
    $68.00M
    -$12.00M
    $51.20M
    -55.4%
    -$54.60M
    -74.4%
    $6.80M
    -90.0%
    -$180.20M
    -1401.7%
    Weakening
    EPS
    $2.16
    $1.25
    $-0.22
    $0.96
    -55.6%
    $0.13
    -89.6%
    $-3.49
    -1486.4%
    Weakening
    Other Income
    $77.90M
    -$18.10M
    $42.80M
    -$18.40M
    -$18.90M
    -124.3%
    -$22.80M
    -26.0%
    $2.90M
    -93.2%
    -$41.20M
    -123.9%
    Weakening
    Interest
    $8.30M
    $14.80M
    $14.70M
    $14.70M
    $15.20M
    +83.1%
    $14.70M
    -0.7%
    $11.00M
    -25.2%
    $10.00M
    -32.0%
    Weakening
    Depreciation
    Profit before Tax
    $142.40M
    -$27.60M
    $92.70M
    -$16.80M
    $57.60M
    -59.6%
    -$50.70M
    -83.7%
    $13.40M
    -85.5%
    -$166.30M
    -889.9%
    Weakening
    MarginsOPM
    21.9%
    -4.9%
    22.5%
    1.1%
    33.1%
    +50.8%
    -18.8%
    -284.4%
    6.7%
    -70.0%
    -53.4%
    -4783.3%
    Weakening
    Tax
    19.4%
    -13.4%
    26.6%
    28.6%
    11.1%
    -42.7%
    -7.7%
    +42.7%
    49.3%
    +84.8%
    -8.4%
    -129.3%
    Stable
    ReturnsROIC
    -34.5%
    9.4%
    -20.4%
    3.6%
    -15.4%
    +55.4%
    16.4%
    +74.4%
    -2.0%
    +90.0%
    54.1%
    +1401.7%
    Strengthening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$112.20M$167.80M$621.30M$576.10M$642.60M$111.70M$99.50M$205.40M$139.70M
    Short-Term Investments
    Total Current Assets$620.80M$686.20M$1.20B$1.27B$1.21B$679.50M$598.70M$662.50M$666.00M
    Net PP&E$510.20M$567.00M$675.10M$828.40M$837.00M$399.00M$282.30M$216.00M$183.80M
    Goodwill$259.70M$266.60M$266.70M$224.90M$218.20M$0$0$0
    Intangibles$761.60M$712.90M$663.10M$604.60M$728.80M$566.60M$501.50M$436.50M$261.80M
    Total Assets$2.23B$2.33B$2.88B$2.96B$3.17B$1.82B$1.39B$1.32B$1.12B
    LiabilitiesTotal Current Liabilities$200.40M$216.30M$384.50M$374.00M$1.23B$651.30M$162.40M$132.20M$122.80M
    Short-Term Debt$10.10M$12.90M$33.80M$31.60M$957.30M$413.70M$0
    Long-Term Debt$784.50M$798.40M$841.00M$809.40M$448.50M$446.50M$663.70M$572.10M$581.80M
    Long-Term Leases$22.10M$27.80M$24.20M$14.80M$13.80M$9.70M$9.20M$4.90M
    Total Liabilities$1.22B$1.24B$1.44B$1.35B$1.78B$1.17B$906.90M$796.00M$775.40M
    EquityCommon Stock & APIC$100.0K$100.0K$100.0K$100.0K$100.0K$100.0K$100.0K$100.0K$100.0K
    Retained Earnings$367.30M$421.80M$726.90M$950.30M$738.70M-$21.80M-$212.40M-$159.80M-$333.20M
    Total Equity$1.01B$1.09B$1.45B$1.61B$1.39B$649.30M$482.80M$522.60M$341.40M
    HighlightsNet Cash / (Debt)-$682.40M-$643.50M-$253.50M-$264.90M-$763.20M-$748.50M-$564.20M

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating$41.80M$188.00M$536.90M$320.20M-$34.10M-$206.30M$58.70M$170.60M$97.70M
    Cash from Investing-$897.20M-$96.90M-$151.90M-$224.10M-$381.30M$212.30M$125.20M$69.40M-$62.00M
    Cash from Financing$788.70M-$35.90M$69.50M-$141.00M$481.20M-$535.70M-$190.00M-$136.60M-$165.60M
    SummaryCapital Expenditure-$72.10M-$86.90M-$141.90M-$224.10M-$115.80M-$51.60M-$22.90M-$13.80M-$11.80M
    Free Cash Flow-$30.30M$101.10M$395.00M$96.10M-$149.90M-$257.90M$35.80M$156.80M$85.90M
    FCF Margin-3.9%9.1%25.0%5.4%-13.4%-24.6%3.4%21.1%11.2%

    Ratios